Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag
Deniz Ece Kaya(London Cancer), Ghulam Mufti(London Cancer), Riley Cook(Centre Hospitalier Universitaire de Toulouse), Fiorenza Barraco(Hôpital Lyon Sud), Nogayhan Seymen(London Cancer), Camilla Frieri(Université Paris Cité), Mohammad M. Karimi(London Cancer), Marleen van Os(Universität Hamburg), Beatrice Drexler(University Hospital of Basel), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Sıla Gerlevik(London Cancer), Austin G. Kulasekararaj(London Cancer), Regis Peffault De Latour(European Society for Blood and Marrow Transplantation), Christian Recher(Centre Hospitalier Universitaire de Toulouse), Jean-Baptiste Méar(Centre Hospitalier Universitaire de Rennes), Carlo Dufour(Istituto Giannina Gaslini), Sofie Terwel(Leiden University), Flore Sicre de Fontbrune(Hôpital Saint-Louis), Antonio M. Risitano(European Society for Blood and Marrow Transplantation), Marica Laurino(Ospedale Policlinico San Martino), Simona Iacobelli(European Society for Blood and Marrow Transplantation), Etienne Daguindau(Centre Hospitalier Universitaire de Besançon), Constantijn J.M. Halkes(Radboud University Nijmegen), Giorgio Napolitani(London Cancer), Morag Griffin(Leeds Teaching Hospitals NHS Trust)
Cited by 2
Related Papers
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study
|Annals of the Rheumatic Diseases|2017|302